AI-Powered Radiation-Free Breast Cancer Screening Device Manufacturing
The Opportunity
India ranks third globally in breast cancer incidence with 26% of all female cancers, yet early detection remains limited by access to radiation-based mammography. Lord's Mark Industries' technology transfer agreement with CMET reveals a gap in affordable, wearable AI-based screening solutions. This represents an opportunity to manufacture and distribute radiation-free diagnostic wearables for mass-market adoption across Indian hospitals, diagnostic centers, and eventually direct-to-consumer channels.
Market Size
₹8,500–12,000 crore. India's breast cancer diagnostic market is estimated at ₹5,000 crore; adding wearable screening devices, subscription monitoring, and hospital contracts could expand TAM by 70–140% over 5 years (source: WCRF India cancer statistics + India diagnostic market reports).
Business Model
Manufacture AI-powered wearable breast screening devices under technology transfer license from CMET. Sell devices to hospitals, diagnostic centers, and corporate wellness programs at ₹15,000–25,000 per unit. Layer in cloud-based SaaS subscription (₹500–1,000/month per patient) for continuous monitoring, AI analysis, and doctor dashboards. Partner with insurance companies for reimbursement eligibility.
1) Device sales: ₹20,000 × 50,000 units/year = ₹10 crore. 2) SaaS subscriptions: ₹750 × 100,000 active users × 12 months = ₹9 crore. 3) Hospital/diagnostic center licensing fees (annual): ₹50 lakh per major center × 200 centers = ₹10 crore.
Your 30-Day Action Plan
Contact CMET and Lord's Mark Industries to understand technology transfer terms, IP licensing, manufacturing protocols, and clinical validation status. Request technical specifications and regulatory roadmap.
Engage regulatory consultants to map CDSCO (Central Drugs Standard Control Organization) requirements for wearable medical devices. Begin preliminary discussions with 3–5 contract manufacturers for device assembly capacity and costing.
Develop financial model for ₹3–5 crore raise. Identify potential anchor customers: 5–10 major diagnostic chains (Apollo, Max, Dr. Lal PathLabs) and corporate wellness programs. Request pilot collaboration letters.
Draft business plan, IP agreement framework, and regulatory submission roadmap. Pitch to healthcare VCs, medical device accelerators, and impact investors. Secure seed funding commitment.
Compliance & Regulatory Angle
CDSCO Class II/III medical device approval (6–12 months); ISO 13485 QMS certification; GST 5% on medical devices; mandatory clinical validation through ICMR or AIIMS partnership; Data Protection Act compliance for cloud-stored patient data; Import duty waiver eligibility under Medical Device Park scheme (if applicable).
Ready to Act on This Opportunity?
Generate a 7-step execution plan — validate the market, build the MVP, model the financials, map the risks, and ship in 30 days.